Alkermes plc is a biopharmaceutical company focused on the central nervous system (CNS) diseases such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by Michael Wall. In September 2011, Alkermes merged with Ilan Pharmaceutical Technologies (EDT), a former pharmaceutical formulation and manufacturing division of Ilan, PLC. Headquartered in Dublin, the company has a R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio. Alkermes has more than 20 commercial drug products and candidates that treat serious and chronic diseases, such as addiction, schizophrenia, diabetes and depression. Among these products, five are the primary of the company: risperidone long-acting injections (generic for Risperdal consta) for schizophrenia and bipolar disorder 1, paliperidone palmitate (generic for Invega Sustenna in the United States, Xeplion in Europe) for schizophrenia, 4-aminopyridine (General for Ambra in the United States, Vambira in Europe) to improve walking in patients with multiple sclerosis, naltrexone for extended injection suspension release (general for vivitrol) for alcohol and dependence on opiates, and exexnatide extended release of injectable suspension (generic for bedorione) for the treatment of type 2 diabetes. Bydureon is a once-a-week, extended release form of the drug, exenatide (Byetta), and was developed through a partnership between Amylin Pharmaceuticals, Alkermes and Eli Lilly. Approved in Europe and the United States Buprenorphine / samidorphan (ALKS-5461), an opioid receptor antagonist, is the next generation, an anti-depressant novel that is under Development by Alkermes for the treatment of treatment-resistant depression. Olanzapine/samidorphan (ALKS-3831) is an atypical antipsychotic blend of modular antipsychotics and modular nepsthat that is under development for the treatment of schizophrenia and bipolar disorder.